This is an old revision of the document!

Biomarker Quick Reference List

; ''PDL1UPPERGIMARCH2026'' : PD-L1 IHC (22C3) — Gastric, GEJ, Esophageal Adenocarcinoma/ESCC. ; ''BMCLAUDIN18'' : Claudin 18.2 IHC — Gastric or GEJ Adenocarcinoma. ; ''PDL1HNSCC22C3PEMBRO'' : PD-L1 IHC (22C3) — Advanced HNSCC. ; ''PDL1HNSCCNEOADPEMBRO'' : PD-L1 IHC (22C3) — Resectable HNSCC (Neoadjuvant). ; ''PDL1CERVIX'' : PD-L1 IHC (22C3) — Cervical Cancer (SCC/Adeno). ; ''MOLARCEP17'' : CEP17 SISH — Ploidy Analysis. ; ''PDL1NSCLCPEMBRO22C3'' : PD-L1 IHC (22C3) — NSCLC Stage IIIb to IV. ; ''PDL1NSCLCATEZOSP263'' : PD-L1 IHC (SP263) — NSCLC Stage II to IIIA (Adjuvant). ; ''PDL1TNBC22C3PEMBRO'' : PD-L1 IHC (22C3) — Triple Negative Breast Cancer (TNBC).

—

Detailed Biomarker Tables

Biomarker	Assay Purpose	Drug(s)	Diagnostic Test	Test ID
PD-L1	Gastric, GEJ, esophageal adenocarcinoma; ESCC	Pembrolizumab, Nivolumab	PDL1 Dako 22C3 PharmDX	''PDL1UPPERGIMARCH2026''
Claudin 18.2	Gastric or GEJ adenocarcinoma	Zolbetuximab	VENTANA CLDN18 (43-14A) RxDx	''BMCLAUDIN18''

Biomarker	Assay Purpose	Drug(s)	Diagnostic Test	Test ID
PD-L1	Advanced HNSCC	Pembrolizumab	PDL1 Dako 22C3 PharmDX	''PDL1HNSCC22C3PEMBRO''
PD-L1	Resectable HNSCC	Pembrolizumab as Neoadjuvant	PDL1 Dako 22C3 PharmDX	''PDL1HNSCCNEOADPEMBRO''

Biomarker	Assay Purpose	Drug(s)	Diagnostic Test	Test ID
PD-L1	Cervical cancer (SCC and Adeno)	Pembrolizumab	PDL1 Dako 22C3 PharmDX	''PDL1CERVIX''
CEP17 SISH	Ploidy Analysis	N/A	VENTANA Inform Chrom. 17	''MOLARCEP17''

Biomarker	Assay Purpose	Drug(s)	Diagnostic Test	Test ID
PD-L1	NSCLC stage IIIb to IV	Pembrolizumab	PDL1 22C3	''PDL1NSCLCPEMBRO22C3''
PD-L1	NSCLC stage II to IIIA	Atezolizumab as Adjuvant	PDL1 SP263	''PDL1NSCLCATEZOSP263''

Biomarker	Assay Purpose	Drug(s)	Diagnostic Test	Test ID
PD-L1	TNBC	Pembrolizumab	PDL1 Dako 22C3 PharmDX	''PDL1TNBC22C3PEMBRO''